FLT3 ligand in acute myeloid leukemia: a simple test with deep implications

被引：7

作者：

Peterlin, Pierre ^{[1
,2
]}

Chevallier, Patrice ^{[1
,2
]}

Knapper, Steven ^{[3
]}

Collin, Matthew ^{[4
,5
]}

机构：

[1] CHU Nantes, Hematol Clin, Nantes, France

[2] Univ Nantes, Univ Angers, CRCINA, INSERM,CNRS, Nantes, France

[3] Cardiff Univ, Sch Med, Div Canc & Genet, Cardiff, Wales

[4] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

[5] Newcastle Univ, NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 02期

关键词：

FLT3; ligand; acute myeloid leukemia; cytokine and chemokine biology; cytokine production and paraneoplastic conditions; prognostication; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM; INHIBITS APOPTOSIS; CELLS; RECEPTOR; EXPRESSION; FLT3-LIGAND; PLASMA; AML; RECOMMENDATIONS;

D O I：

10.1080/10428194.2020.1834091

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In contrast to Fms-like tyrosine kinase 3 (FLT3), the influence of FLT3 ligand (FLT3L) on acute myeloid leukemia (AML) biology and disease prognosis has been poorly described. Here we provide an overview of the role played by FLT3L in AML. While being a cytokine implicated in the regulation of hematopoiesis, both in normal situation and after intensive chemotherapy, FLT3L has also a role in enhancing proliferation, inhibiting apoptosis and conferring resistance to FLT3 inhibitors in AML. Moreover, recent independent data show how its measurement may be helpful in the disease management. Indeed, FLT3L could provide a low cost, rapid and noninvasive assessment of chemosensitivity and blast clearance that has robust prognostic significance for patients with AML.

引用

页码：264 / 270

页数：7

共 49 条

[1] Level of Flt3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia [J].

Bertho, JM ;

Demarquay, C ;

Frick, J ;

Joubert, C ;

Arenales, S ;

Jacquet, N ;

Sorokine-Durm, I ;

Chau, Q ;

Lopez, M ;

Aigueperse, J ;

Gorin, NC ;

Gourmelon, P .

INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2001, 77 (06) :703-712

[2]

BRASEL K, 1995, LEUKEMIA, V9, P1212

[3]

Bruserud O, 2003, HAEMATOLOGICA, V88, P416

[4]

Bruserud O, 2001, EUR CYTOKINE NETW, V12, P231

[5] Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells [J].

Chen, Fangli ;

Ishikawa, Yuichi ;

Akashi, Akimi ;

Naoe, Tomoki ;

Kiyoi, Hitoshi .

ONCOTARGET, 2016, 7 (30) :47018-47032

[6] 90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study [J].

Chevallier, Patrice ;

Eugene, Thomas ;

Robillard, Nelly ;

Isnard, Francoise ;

Nicolini, Franck ;

Escoffre-Barbe, Martine ;

Huguet, Franoise ;

Hunault, Mathilde ;

Marcais, Antoine ;

Gaschet, Joelle ;

Cherel, Michel ;

Guillaume, Thierry ;

Delaunay, Jacques ;

Peterlin, Pierre ;

Eveillard, Marion ;

Thomas, Xavier ;

Ifrah, Norbert ;

Lapusan, Simona ;

Bodet-Milin, Caroline ;

Barbet, Jacques ;

Faivre-Chauvet, Alain ;

Ferrer, Ludovic ;

Bene, Marie C. ;

Le Houerou, Claire ;

Goldenberg, David M. ;

Wegener, William A. ;

Kraeber-Bodere, Franoise .

LANCET HAEMATOLOGY, 2015, 2 (03) :E108-E117

[7] Targeting FLT3 mutations in AML: review of current knowledge and evidence [J].

Daver, Naval ;

Schlenk, Richard F. ;

Russell, Nigel H. ;

Levis, Mark J. .

LEUKEMIA, 2019, 33 (02) :299-312

[8]

Dehmel U, 1996, LEUKEMIA, V10, P261

[9]

Dehmel U, 1996, LEUKEMIA, V10, P271

[10] In vitro and in vivo evaluation of possible pro-survival activities of PGE2, EGF, TPO and FLT3L on human hematopoiesis [J].

Demmerath, Eva-Maria ;

Bohler, Sheila ;

Kunze, Mirjam ;

Erlacher, Miriam .

HAEMATOLOGICA, 2019, 104 (04) :669-677

← 1 2 3 4 5 →